INTRODUCTION

Suicidality can be differentiated into definite suicidal behavior, suicidal ideation, plan and suicidal intent, the “subjective expectation and desire for a self-destructive act to end in death” (APA 2003). Applying antidepressants (AD) to children and adolescents have been shown to be associated with a paradoxical burgeoning of suicidality (Hetrick et al. 2012). According to this Cochrane review including young population with major depressive disorders (MDD), there was an increased risk (58%) of suicide-related outcome for those on AD compared with a placebo (relative risk 1.58; 95% CI 1.02 to 2.45) (Hetrick et al. 2012). In 2014, a large British cohort study confirmed a significant positive relationship between the use of different ADs and the risk of suicide in adult MDD-patients (Coupland et al. 2015). To precise, absolute risks of attempted suicide or self-harm over one year ranged from 1.02% for amitriptyline, 1.41% for sertraline, 1.61% for escitalopram, 2.64% for trazodone, 2.55% for mirtazapine to 2.96% for venlafaxine (Coupland et al. 2015). In this context, there is a vigorous debate about whether and how AD can trigger suicidality in various age groups (Mihanović et al. 2010, Goldsmith & Moncrieff 2011, Nischal et al. 2012, Fornaro et al. 2019). Here, we describe the shift from chronic suicidal ideation to compulsive suicidal intent during an augmentation treatment using venlafaxine-extended release (ER) in an adult MDD-patient under pharmacotherapy with lithium, mirtazapine and L-thyroxin.

CASE PRESENTATION

A 45-year-old white male with normal BMI was admitted due to a severe relapse of a recurring MDD, which occurred under lithium (serum level: 0.82 mM) and 45 mg mirtazapine, both taken at bedtime, together with frequent medical/psychiatric counselling & psychoeducation as well as long-term psychotherapy. Co-morbid alcohol use disorder and social phobia were in remission in contrast to an active autoimmune polyglandular syndrome (APS) subtype 4 with vitiligo acrofacialis, Hashimoto thyroiditis and lymphocytic colitis (Betterle et al. 2014). Beyond this, the physical examination was unremarkable. Routine lab revealed an increased thyroid-stimulating hormone (TSH 25 mU/L) despite thyroid-hormone-replacement therapy with 200µg/day L-thyroxine and a slightly increased CRP. The remaining lab was normal including vitamin B serum-levels and autoimmune diagnostics even with respect to Addison’s disease and diabetes mellitus (Betterle et al. 2014). Upon admission, the patient was severely depressed (Hamilton Depression Score; HAM-D21item 39 points) with dominant loss of energy, social withdrawal, loss of appetite, great lacks of drive and motivation, feeling of worthlessness, great difficulty to concentrate, diffuse anxious agitation, high stress vulnerability, insomnia and chronic suicidal ideation (APA 2003). Initially, the patient was relaxed by lorazepam 0.5 mg q.i.d. in parallel to an augmentation with venlafaxine-ER, which was established stepwise from 37.5 mg/day up to 225 mg/day within three weeks. At 150 mg venlafaxine-ER/day, the patient reported a partial improvement of mood, concentration, insomnia and appetite and motivation (HAM-D21item 24 points) but developed strong impulse and desire for suicide by jumping from a height which was accompanied by further adverse effects (restlessness, anxiety, sweating, hand jitter) (Sinclair et al 2009). He was deeply irritated because he had never experienced a similar compulsive quality of suicidality before. The urge to suicide was dose-dependent, since increasing from 150 mg/d to 225 mg/day venlafaxine-ER and then, completely disappearing after tapering off venlafaxine-ER. The same applied to the accompanying jitteriness/ anxiety and sweating which was controlled by lorazepam for PRN-medication - just as the strong suicidal
The daily lorazepam relaxation (0.5 mg q.i.d.) was gradually discontinued. Within the next 6 weeks of multimodal inpatient treatment (psycho-, occupational-, movement-, milieu-therapy), the MDD gradually remitted (down to HAM-D21 item 6 points) (Zajecka 2003) without venlafaxine or any other pharmacological augmentation-strategy. Simultaneously, the suicidal thoughts, which persisted with varying severity for several years before, lost its intensity up to discharge. In addition, concurrent to an increasing stress tolerance, the vitiligo faded slightly and the patient became spontaneously euthyroid even without an escalation of thyroid hormone-replacement. This course of the augmentation with venlafaxine-ER was rather surprising for us because the patient had a combined treatment with venlafaxine-ER (up to 300 mg/day), L-thyroxin and mirtazapine a few years ago, however, not together with lithium and not complicated by a worsening of suicidality.

At discharge, we reviewed the treatment together with the patient and asked him again for any psychosocial event that might have promoted the suicidal intent independent on increasing the venlafaxine dose. He denied this again and underlined that the suicidal intent had exclusively emerged along with the venlafaxine dose-escalation. He could exclude that the accompanying adverse effects (jitteriness/anxiety; sweating) had amplified his suicidality or that he wanted to end his life as a consequence of being more activated.

DISCUSSION

Indeed, lithium reduces suicide risk (Sadkowski et al. 2013, Tondo & Baldessarini 2018). The exact mechanism, however, remains obscure as yet, eventually involving the modulation of the monoamine neurotransmission system from intracellular, the strengthening of the cellular oxidative stress defense and a limbic glutamate surge (Sadkowski et al. 2013, Machado-Vieira et al. 2015, 2017, Szulc et al. 2018) - all, by the way, by analogy with ketamine (Weckmann et al. 2017, Bonnet 2017a). There is convincing evidence that alterations of the brain serotonin-allostasis are involved in the generation of suicidal behavior (Sadkowski et al 2013, van Heeringen & Mann 2014). We also assume a change in the balance in the orchestra of susceptible serotonin receptor-subtypes to be responsible for the venlafaxine-induced progression from suicidal ideation to suicidal intent in our case presentation. Such sensitivity-changes in receptor signaling are not unusual in the long-term stimulation or under-stimulation of neurotransmitter brain networks and most likely underlay paradoxical adverse reactions, citing e.g. the cannabis hyperemesis syndrome (Bonnet 2014b), opioid-induced hyperalgesia (Johnson et al. 2013), analgesic-induced headache (Johnson et al 2013), neuroleptic-induced catatonia (Lee 2010) and, perhaps, the drift from ketamine’s favorable antidepressant and anti-suicidal response to addiction-related dysphoria and suicidality (Jansen 2000, Bonnet 2017a). A more common hypothesis of the amplification of suicidality during the titration of ADs relies on their activating effects including akathisia and jitteriness, but this has not been evaluated by controlled studies so far (Sinclair 2009, Goldsmith & Moncrieff 2011). The patient himself did not claim such a functional relation with his suicidal intent although it cannot be totally excluded that unpleasant emotions accompanying the venlafaxine-related adverse effects had been unconscious cues or incentives for his increase in suicidality.

Acknowledgements:

We would like to thank the patient who gave us his written informed consent to introduce his case here.

Conflict of interest: None to declare.

Contribution of individual authors:

Udo Bonnet: concept, manuscript writing, literature search.

Uwe Knierim: manuscript revising, literature search.

References

2. Betterle C, Garelli S1, Coco G, Burra P. A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3). Auto Immun Highlights 2014; 5:27-31

Correspondence:
Prof. Udo Bonnet, MD
Department of Psychiatry, Psychotherapy and Psychosomatic Medicine,
Evangelisches Krankenhaus Castrop-Rauxel
44577 Castrop-Rauxel, Germany
E-mail: udo.bonnet@uni-due.de